Biocon reports 95% yo -yard of the net profit, operational turnover by 15% higher

Biocon achieved a decrease of 95% on an annual basis in reported net profit in the first quarter of June. However, the company claims to have booked an increase of 65% profit after tax on a similar basis, after adjusting the one-off disinvestment profits that it achieved a year ago in the same quarter through the sale of metabolic, oncology and critical care portfolio of its brand formulations India (BFI) company to Eris-Levensduur.

The operational turnover of the Q1FY26 company grew by 15% on an annual basis to RS 3,942 Crore, while EBITDA was on RS 829 Crore for the quarter, with 19% with an EBITDA margin of 21% on a comparable basis, the company said in a statement.

“The recent QIP has strengthened our balance and enables us to increase our property in biocon biology by facilitating the output of structured stock investors, so that the capital structure is tailored to strategic priorities in the long term,” said Kiran Mazumdar-Shaw, chairman, Biocon Group.

“With implementation momentum for all companies and extensive capacity through acquisitions in the US by Syngene and Biocon-General Medicines, we are well positioned to stimulate the long-term value creation and then,” Shaw said.

Biocon concluded its first stock funds since the IPO of 2004, as a result of which RS 4,500 crores called on qualified settings (QIP) in June. The funds will be used to increase the importance of biocon in biocon biologics and to offer an exit for the private equity investors in biocon biologics, the company said.

The company’s API & generic formulations business reported 6% growth in revenue from operations to Rs 697 crore.“Growth in the quarter was primarily driven by revenues from recent drug product launches, including liraglutide in the EU, and dasatinib and lenalidomide in the US, supported by higher Volumes in our API Business, “Said Siddharth Mittal, CEO & Managing Director, Biocon.” We Remain focused on launching new products, including the commercialization of Liraglutide on important strategic markets, “he added.

Biocon Biologics achieved 18% year-on-year sales growth, powered by a robust demand on important markets.

The CRDMO Business Syngene’s turnover from the activities from the activities grew by 11% on an annual basis to RS 875 CRORE and EBITDA was on RS 224 CRORE, which reported a 19% growth.

“Growth was driven by a continuous momentum in research services, because pilot programs switched to long -term contracts,” said Peter Bains, CEO & Managing Director, Syngene International.